Future medicinal chemistry最新文献

{"title":"Design and synthesis of novel 3,5-diphenyl pyrazolines acting as potent EGFR inhibitors with off-target antileukemic effect.","authors":"Basma S Gabr, Abdelrahman R Shalabi, Mona F Said, Mohamed S Nafie, Riham F George","doi":"10.1080/17568919.2025.2559579","DOIUrl":"10.1080/17568919.2025.2559579","url":null,"abstract":"<p><strong>Aim: </strong>Searching for novel epidermal growth factor receptor (EGFR) inhibitors, 1-substituted 3,5-diphenyl pyrazolines <b>4a-i</b>, <b>5a-i</b>, <b>6a</b>, and <b>6b</b> bearing the terminal piperidine or morpholine moieties commonly observed in clinically approved EGFR inhibitors were synthesized as novel anti-cancer agents acting via EGFR inhibition.</p><p><strong>Materials & methods: </strong>A series of 3,5-diphenyl pyrazolines was synthesized and screened for <i>in vitro</i> anti-cancer activity against 60 NCI cell lines.</p><p><strong>Results: </strong>Pyrazolines <b>5d</b> and <b>6a</b> revealed broad-spectrum cytotoxic activities and potent EGFR inhibition with IC₅₀ values of 2.30 µM and 1.47 µM, respectively, in comparison to Vandetanib (IC₅₀ = 0.5 µM) and Gefitinib (IC₅₀ = 0.04 µM). Interestingly, compound <b>6a</b> demonstrated a promising cytotoxic activity against the leukemia cell line (HL-60) and safety toward the normal cell line HSF. Additionally, compound <b>6a</b> up-regulated proapoptotic markers and down-regulated Bcl-2 as an antiapoptotic marker in HL-60 cells. Docking simulations explained the EGFR inhibitory actions of <b>5d</b> and <b>6a</b> compared to Gefitinib. According to predictive models of oral bioavailability and drug-likeness, pyrazolines <b>5d</b> and <b>6a</b> are expected to be bioavailable and drug-like compounds.</p><p><strong>Conclusion: </strong>Pyrazolines <b>5d</b> and <b>6a</b> are novel EGFR inhibitors with a broad-spectrum anti-cancer activity, and <b>6a</b> has off-target antileukemic effect.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2345-2360"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyrrolidine-based hybrid compounds: design, synthesis, in vitro and in vivo pharmacological properties and molecular docking studies.","authors":"Senanur Taş, H Ali Döndaş, Naciye Yaktubay Döndaş, Samet Poyraz, Tuğba Taşkın Tok, Gülüzar Atlı Demiray, Samet Belveren, Tuncay İnce, Yeliz Demir, Mehmet Bertan Yılmaz, Mahmut Ülger, Mehmet Ali Tamer, José M Sansano, Christopher M Pask","doi":"10.1080/17568919.2025.2559573","DOIUrl":"10.1080/17568919.2025.2559573","url":null,"abstract":"<p><strong>Aims: </strong>To design, synthesize, and evaluate pyrrolidine-based hybrids bearing indole, thiourea, and vinyl sulfone pharmacophores as dual inhibitors of human carbonic anhydrase I/II (hCAI/II) and acetylcholinesterase (AChE), with secondary profiling of complementary bioactivities.</p><p><strong>Materials & methods: </strong>Three hybrids (6a, 6b, 8) were obtained <i>via</i> imine azomethine ylide 1,3-dipolar cycloaddition and derivatization. Structures were confirmed spectroscopically and assayed <i>in vitro</i> for hCAI/II and AChE inhibition. Additional evaluations included antioxidant (DPPH), antibacterial, antifungal, antituberculosis (<i>M. tuberculosis</i> H37Rv), cytotoxicity (HCT116, DPSCs), anti-inflammatory (COX-2, SOD1 ELISA, mouse xylene-induced), antidepressant (forced swim test), molecular docking, and <i>in silico</i> ADMET.</p><p><strong>Results: </strong>Compound 6b was the most potent inhibitor (hCAII <i>K</i>i 75.79 ± 2.83 nM, AChE <i>K</i>i 43.17 ± 10.44 nM), outperforming acetazolamide (<i>K</i>i 299.33 ± 45.44 nM) and tacrine (<i>K</i>i 103.47 ± 11.54 nM). Compound 6a showed the strongest antioxidant effect (72.30% DPPH), antibacterial activity against <i>A. baumannii</i> (MIC 125 µg/ml, comparable to ampicillin), and superior anti-TB potency (MIC 31.25 µg/ml). Compound 6b exhibited stronger antibacterial activity (MIC 62.5 µg/ml). Both reduced COX-2 levels, and 6a increased SOD1. The hybrids were selectively cytotoxic to HCT116, sparing DPSCs. Docking studies confirmed key binding interactions, while ADMET predicted favorable profiles.     .</p><p><strong>Conclusions: </strong>The hybrids validate a focused dual-target strategy. Compound 6b is the most potent hCAII and AChE inhibitor, while 6a emerges as a broader multi-target lead with antioxidant, antimicrobial, anti-inflammatory, and antidepressant potential.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2361-2377"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desmuramylpeptide, a NOD2 agonist, enhanced immune response and parasite clearance in <i>Leishmania donovani</i> infection.","authors":"Sandeep Kaur, Aarzoo Kamboj, Shivani Thakur, Deepak B Salunke, Sukhbir Kaur","doi":"10.1080/17568919.2025.2559574","DOIUrl":"10.1080/17568919.2025.2559574","url":null,"abstract":"<p><strong>Introduction: </strong>Visceral leishmaniasis is a life-threatening infectious disease caused by the intracellular protozoan <i>Leishmania</i>, where interactions between the parasite and the host's intracellular components play a crucial role in tracking the incursion of infection. Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) plays a critical role in regulating inflammation and eliciting a defensive immune response to the pathogen. Consequently, we aimed to explore the role of a desmuramylpeptide (NOD2 agonist) in visceral leishmaniaisis caused by <i>Leishmania donovani</i>.</p><p><strong>Methodology: </strong>In this study, wedescribe the multistep solution-phase synthesis of a potent desmuramylpeptide (<b>Compound</b> <b>6</b>) derived from trans-ferulic acid. This compound was subsequently evaluated for its <i>in vitro</i> biological activities against <i>Leishmania donovani</i>.</p><p><strong>Results: </strong><b>Compound 6</b> demonstrated potent <i>in vitro</i> activity against <i>L. donovani</i> parasites (promastigote and amastigote forms) leading to successful clearance of parasites. Furthermore, it exhibited immunostimulatory effects by enhancing reactive oxygen species and nitric oxide production while showing moderate cytotoxicity against RAW 264.7 macrophages and HeLa cells. Notably, <b>Compound 6</b> was more effective than muramyl dipeptide in promoting parasite clearance and eliciting robust immunomodulatory response.</p><p><strong>Conclusion: </strong>Overall, the study highlights NOD2 as a critical mediator of immune modulation during <i>Leishmania</i> infection, suggesting its potential as a pharmacological target for host-directed immune intervention.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2333-2343"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel thiazolidine-4-carboxylic acid derivatives: synthesis and inhibitory effects against influenza A.","authors":"Muazzam Arif, Humaira Nadeem, Zaman Ashraf, Muhammad Tariq Khan, Tayyaba Anwar, Rizwan Hafeez","doi":"10.1080/17568919.2025.2559575","DOIUrl":"10.1080/17568919.2025.2559575","url":null,"abstract":"<p><strong>Aims: </strong>This study explored the synthesis and evaluation of novel neuraminidase (NA) inhibitors, focusing on thiazolidine-4-carboxylic acid derivatives to combat influenza.</p><p><strong>Materials and methods: </strong>The synthesized compounds were evaluated for their NA inhibitory activity and assessed against Influenza A (H7N3) using hemagglutination inhibition (HAI) assays. Molecular docking studies were also conducted to support the experimental findings.</p><p><strong>Results: </strong>Compounds 4a, 4b, and 6a demonstrated potent NA inhibitory activity. While all compounds showed moderate HAI activity compared to Oseltamivir, 4a and 8a exhibited strong potency with low Mean MIC values against the H7N3 strain.</p><p><strong>Conclusions: </strong>These findings suggest that the thiazolidine derivatives hold potential as novel inhibitory agents against influenza. Future research will focus on assessing their toxicity and safety profiles, paving the way for the development of effective and safer NA inhibitors.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2379-2389"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in the design of small molecules targeting human ClpP.","authors":"Ziyi Shu, Jiangnan Zhang, Yi Wu, Tao Yang, Youfu Luo","doi":"10.1080/17568919.2025.2557175","DOIUrl":"10.1080/17568919.2025.2557175","url":null,"abstract":"<p><p>Human mitochondrial ClpP (hClpP), a pivotal protease regulating mitochondrial protein homeostasis, has emerged as an important target for anticancer drug development. In recent years, significant progress has been made in designing small molecules targeting hClpP, primarily classified into activators and inhibitors. Activators specifically stimulate ClpP proteolytic activity by mimicking the mechanism of its chaperone protein ClpX, with representative compounds, such as imipridone derivatives (ONC201/206/212) and their optimized products (ZK53, 7k, etc.) demonstrating excellent antitumor efficacy. Investigation of their structural design and pharmacological properties provides theoretical insights for subsequent drug development. Significant progress has been made in agonist research, and although there are still issues that need to be addressed, hClpP-targeted drugs hold promise as new therapies for the treatment of cancer.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2407-2424"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latest developments in small molecule analgesics: heterocyclic scaffolds II.","authors":"Asaf Evrim Evren, Arzu Hıdır, Berkant Kurban, Begüm Nurpelin Sağlık Özkan, Serkan Levent, Adem Şahin, Yusuf Özkay, Nalan Gündoğdu-Karaburun","doi":"10.1080/17568919.2025.2559570","DOIUrl":"10.1080/17568919.2025.2559570","url":null,"abstract":"<p><p>In this review, the primary aim is to examine non-azole ring systems that have analgesic activity and, where applicable, to establish structure - activity relationships (SARs) with the nine major pathways, prostaglandin synthesis inhibition, opioid receptor modulation, sodium channel blockade, enhancement of serotonin and norepinephrine levels, cannabinoid receptor (CBR) binding, N-methyl-D-aspartate (NMDA) receptor antagonism, transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonism, and P2X purinergic receptor blockade, have been described for pain relief. Analgesic effects have been observed in compounds containing ring systems such as piperidine, piperazine, pyridine, pyridazine, pyrazine, morpholine, thiomorpholine, pyran, thiopyran, indane, benzofuran, benzothiophene, quinoline, quinazoline, and chromene. These ring systems were classified in the whole study, first according to their molecular weights and then by bioisosteric similarity as same as first part. Differing from the initial study of this work, the advantages of newly developed and approved drug formulations were evaluated, and recent advances in analgesic drug development were discussed. Accordingly, this review also provides a framework for the formulation of compounds incorporating these core structures in the design of novel molecules with potential analgesic properties. In conclusion, these works highlight the current progress and emerging strategies in analgesic drug discovery and development.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2391-2405"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Schiff bases and cancer drug resistance: key preclinical breakthroughs.","authors":"Bianca Stiller, Sonja Hager, Nenad R Filipović, Christian R Kowol, Petra Heffeter","doi":"10.1080/17568919.2025.2561540","DOIUrl":"https://doi.org/10.1080/17568919.2025.2561540","url":null,"abstract":"","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1-4"},"PeriodicalIF":3.4,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and evaluation of 2-(4-((2-(2-((2,6-dichloro-3-methylphenyl)amino)benzoyl)hydrazineylidene)methyl)phenoxy)acetic acid as a dual anti-inflammatory and anti-diabetic agent.","authors":"Mohamed K Elgohary, Mahmoud S Elkotamy, Mahmoud Abdelrahman Alkabbani, Ahmed Mohamed El-Khatib, Aya Mohamed Ahmed Ibrahim, Ali Mohamed Alshabi, Abdulrahman A Almehizia, Ahmed M Naglah, Hazem A Ghabbour, Hatem A Abdel-Aziz","doi":"10.1080/17568919.2025.2561543","DOIUrl":"10.1080/17568919.2025.2561543","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to design, synthesize, and evaluate a novel meclofenamic acid derivative (7) for its potential as a dual-target therapeutic agent with anti-inflammatory, antidiabetic, antioxidant, and anticancer activities.</p><p><strong>Materials & methods: </strong>Compound 7 was synthesized and subjected to in vitro, in vivo, and in silico evaluations. Anti-inflammatory activity was assessed using acute and chronic models, including IL-6 and NF-κB quantification and histopathology. Antidiabetic potential was evaluated through α-glucosidase inhibition, glucose tolerance, and alloxan-induced diabetic models. Antioxidant activity was tested against ascorbic acid, while cytotoxicity was assessed on MCF-7, T24, and A-549 cell lines. Molecular docking, ADME profiling, and pathway analyses were performed to predict drug-likeness and target interactions.</p><p><strong>Results: </strong>Compound 7 exhibited potent anti-inflammatory activity (IC₅₀ = 0.07 µM), reducing IL-6 and NF-κB by 62.99% and 59.13%, respectively. It demonstrated strong α-glucosidase inhibition (IC₅₀ = 12.78 µM) and improved insulin regulation. Antioxidant activity was comparable to ascorbic acid. Cytotoxicity studies revealed moderate anticancer activity with synergistic enhancement when combined with cisplatin.</p><p><strong>Conclusions: </strong>Computational and experimental findings suggest that compound 7 exhibits favorable drug-like properties and holds promise as a multi-target therapeutic candidate.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1-12"},"PeriodicalIF":3.4,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and synthesis of novel <i>N</i>-phenyl-4-pyrimidine-diamine BCL6 inhibitors with <i>anti</i>-tumor activities.","authors":"Yan Li, Yajing Xing, Dongxia Huang, Jiuqing Xie, Yangrui Peng, Zhengfang Yi, Yihua Chen","doi":"10.1080/17568919.2025.2561541","DOIUrl":"https://doi.org/10.1080/17568919.2025.2561541","url":null,"abstract":"<p><strong>Aim: </strong>To develop potent B cell lymphoma 6 (BCL6) inhibitors, novel <i>N</i>-phenyl-4-pyrimidine-diamine analogs were designed and synthesized via structure-based and computer-aided drug design.</p><p><strong>Methods: </strong>Starting from the hit compound <b>ZB979</b>, we synthesized three series of pyrimidinediamine BCL6 inhibitors (<b>13a-13e, 14a-14c</b> and <b>15a-15g</b>) and evaluated their inhibitory activities on BCL6-SMRT interaction using homogeneous time-resolved fluorescence (HTRF) assays. The most promising candidate, compound <b>15d</b>, was further assessed for its anti-proliferative activity and modulation of BCL6 downstream target genes, suppression of germinal center (GC) formation.</p><p><strong>Results: </strong>Compound <b>15d</b> demonstrated significant BCL6-SMRT inhibition with favorable physicochemical properties (Calculated LogP (ClogP) and topological polar surface area (tPSA)).</p><p><strong>Conclusion: </strong>These findings highlight the potential of pyrimidinediamine-based scaffolds as novel BCL6 inhibitors, warranting further structural optimization to improve their efficacy.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1-12"},"PeriodicalIF":3.4,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-alkaline phosphatases (ALP) potentials of potent 4-aminobenzenesulfonamide derivatives against <i>Naja oxiana</i> venom.","authors":"Saqib Khan, Muhammad Yaqoob, Muhammad H H B Asad, Rafia Falak, Zaman Ashraf, Abdul Mannan, Syed M Bukhari, Fiaz Alam, Umer Rashid","doi":"10.1080/17568919.2025.2561395","DOIUrl":"https://doi.org/10.1080/17568919.2025.2561395","url":null,"abstract":"<p><strong>Aim: </strong><i>Naja oxiana</i> venom-induced alkaline phosphatase (ALP) enzyme has been documented for its detrimental effects post envenomation in the victims. Therefore, the present study was designed to evaluate the effectiveness of 4-aminobenzenesulfonamide-based derivatives against cobra venom-induced ALP enzyme.</p><p><strong>Methods: </strong>Targeted derivatives were synthesized and characterized via FTIR, ¹H NMR, and ¹³C NMR followed by docking targeted protein techniques. Furthermore, synthetic analogues were evaluated in vitro for their potential to halt ALP activity.</p><p><strong>Results: </strong>Among all the synthetic compounds, (SB-5) showed remarkably potent inhibitory activity against the targeted enzyme (94%, IC₅₀, 3.25 µM, <i>p</i> < 0.001). Furthermore, kinetic studies revealed that (SB-5) acts as a mixed-type inhibitor of ALP enzyme. Its Ki value (13.19 µM) indicated a high binding affinity, accompanied by a favorable safety profile - characterized by high gastrointestinal (GI) absorption, compliance with Lipinski's Rule of Five (0 violations), and a low likelihood of crossing the blood-brain barrier, suggesting good oral bioavailability. The Ramachandran plot offered further insight into the positioning of amino acid residues within the most favored regions, thereby reinforcing the potential to inhibit ALP activity.</p><p><strong>Conclusion: </strong>The present study confirms the effectiveness of 4-aminobenzenesulfonamide-based derivative (SB-5) as a promising inhibitor of ALP and as a lead candidate for future drug development.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}